Following this activity, participants should be able to: (1) Describe the distinct molecular features of classical hairy cell leukemia and hairy cell leukemia variant. (2) Discuss the current treatment options and the need for the development of novel agents for the treatment of classical hairy cell leukemia. (3) Review the evidence from clinical trials supporting the use of small molecule inhibitors for the treatment of classical hairy cell leukemia (newly diagnosed, relapsed/refractory and progressive disease).
- Provider:National Comprehensive Cancer Network
- Activity Link: https://education.nccn.org/node/95297
- Start Date: 2024-05-29 05:00:00
- End Date: 2024-05-29 05:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: AstraZeneca (Any division) - Amount: 0.0 - Is Kind Support: False Source: Exelixis - Amount: 0.0 - Is Kind Support: False Source: GlaxoSmithKline - Amount: 0.0 - Is Kind Support: False Source: Lantheus - Amount: 0.0 - Is Kind Support: False Source: Merck (Any division) - Amount: 0.0 - Is Kind Support: False Source: Novartis Corporation Pharmaceuticals - Amount: 0.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest